First Horizon Advisors Inc. Sells 206 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Horizon Advisors Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 13,437 shares of the biopharmaceutical company’s stock after selling 206 shares during the quarter. First Horizon Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $14,126,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Quent Capital LLC increased its stake in Regeneron Pharmaceuticals by 5.1% in the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 19 shares during the period. Bessemer Group Inc. increased its stake in Regeneron Pharmaceuticals by 107.1% during the 1st quarter. Bessemer Group Inc. now owns 5,075 shares of the biopharmaceutical company’s stock valued at $4,886,000 after purchasing an additional 2,624 shares in the last quarter. Lake Street Advisors Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 41.3% in the first quarter. Lake Street Advisors Group LLC now owns 746 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 218 shares during the last quarter. Pitcairn Co. raised its position in Regeneron Pharmaceuticals by 6.5% during the 1st quarter. Pitcairn Co. now owns 838 shares of the biopharmaceutical company’s stock worth $807,000 after buying an additional 51 shares during the last quarter. Finally, Ossiam boosted its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the 1st quarter. Ossiam now owns 5,429 shares of the biopharmaceutical company’s stock valued at $5,225,000 after acquiring an additional 302 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on REGN shares. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $744.60 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $736.19 and a twelve month high of $1,211.20. The firm has a market capitalization of $81.82 billion, a price-to-earnings ratio of 18.43, a PEG ratio of 2.86 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm’s fifty day simple moving average is $969.72 and its 200-day simple moving average is $1,032.16.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.